Failure to Diagnose Breast Cancer: A Case-Screening Guide

Cancers are one of the "Big Three" categories of serious diagnostic error, and breast cancer is among the most frequently litigated of all delayed-diagnosis claims. Delayed breast-cancer diagnosis is a leading cause of malpractice litigation against both clinicians and radiologists, and the reason is structural: the disease is common, the screening is imperfect, and a single false-reassurance moment — "your mammogram was normal" — can send a curable cancer untreated for a year or more.

Frequency & severity

Breast cancer is the second-leading cause of cancer death in women, and missed or delayed diagnosis is a major source of patient harm and litigation. Roughly 20–30% of breast cancers can be missed at screening mammography, largely because dense breast tissue obscures the tumor. The harm in these cases is defined by stage shift: a cancer that would have been a small, node-negative, highly curable tumor at the time of the missed clue can become a larger, node-positive, or metastatic cancer requiring far more aggressive treatment by the time it is finally found. That progression is the engine of both the damages and the causation argument.

The cannot-miss clinical picture & red flags

The litigated breast-cancer case is rarely a screening-only failure — it is usually a palpable or symptomatic finding that was not pursued to completion. Red flags that demand a full workup:

• A dominant, persistent, palpable lump — felt by the patient or clinician, that does not resolve. This must be worked up regardless of a normal mammogram.
• A "normal" mammogram in a symptomatic breast — the single most dangerous reassurance. False-negative rates for palpable masses run as high as roughly 22%.
• Dense breast tissue — reduces mammographic sensitivity and is itself a risk factor; supplemental ultrasound (and sometimes MRI) is often indicated.
• Skin changes, nipple retraction or new inversion, bloody nipple discharge, or peau d'orange — the latter classic for inflammatory breast cancer, which is frequently misdiagnosed as mastitis or infection and "treated" with antibiotics.
• An axillary mass or lymphadenopathy without an obvious benign cause.
• BI-RADS findings that called for short-interval follow-up or biopsy that was never tracked, scheduled, or completed.

The core standard-of-care principle: a dominant, persistent, palpable mass must be evaluated to completion — typically through triple assessment (clinical exam, imaging, and tissue biopsy) — and a negative mammogram alone does not end the inquiry. Telling a woman with a real lump to "watch it" because imaging was clean is the recurring breach.

Dominant allegation types

• Over-reliance on a normal mammogram in a patient with a palpable lump — no ultrasound, no biopsy, reassurance, and a long delay.
• Failure to order indicated supplemental imaging — especially in dense breasts where ultrasound or MRI was warranted.
• Radiologic miss or misinterpretation — a lesion visible in retrospect that was read as benign or normal, or a BI-RADS recommendation that was never communicated or acted on.
• Failure to close the loop — an abnormal result, a recommended biopsy, or a short-interval follow-up that fell through tracking and was never completed.
• Misdiagnosis of inflammatory breast cancer as infection — repeated antibiotic courses for "mastitis" without imaging or biopsy of non-resolving findings.

What makes a strong vs. weak case

A strong case has the elements aligned and, critically, a meaningful stage difference:

• Breach: a documented palpable mass, suspicious imaging finding, or red-flag symptom that the standard of care required to be worked up to completion, and a record showing the workup was not done or not tracked.
• Causation: proof that timely diagnosis would more likely than not have caught the cancer at an earlier, more curable stage — a node-negative versus node-positive shift, a curable versus metastatic difference, or, in loss-of-chance jurisdictions, a quantifiable reduction in the chance of cure.
• Damages: more aggressive treatment, reduced survival, recurrence, or death.

A weak or defensible case typically involves a short delay that did not change stage or prognosis; an aggressive, fast-growing tumor where earlier diagnosis would not have altered the outcome; a complete and reasonable workup that simply did not reveal the cancer; or significant patient non-adherence (missed appointments, declined biopsy, deferred follow-up). Because the damages hinge on what the delay actually cost in staging and prognosis, an oncology and pathology causation analysis is essential before the case is worth pursuing.

Contributing factors

Recurring system factors include reflexive over-trust in a negative mammogram; the genuine difficulty of dense-breast imaging; cognitive biases in image interpretation (satisfaction of search, anchoring); broken result-tracking and referral loops in busy practices; and the framing of a young patient as "too young" for breast cancer. Each can turn a recoverable cancer into an advanced one over a period of months.

The records angle

The chart should establish when the lump or finding first appeared, how it was documented, what imaging was ordered and exactly how it was interpreted (including any BI-RADS category and follow-up recommendation), whether ultrasound, MRI, or biopsy was ordered and completed, and how — or whether — abnormal results and recommendations were communicated and tracked. A precise chronology aligning the first clue against the eventual diagnosis defines the delay interval; the pathology and staging documents anchor the causation analysis; and the EHR audit trail confirms when entries were made and whether anything was amended after the diagnosis.

The bottom line

The viable delayed-breast-cancer case usually comes down to one false-reassurance decision — dismissing a real, palpable lump on the strength of a normal mammogram — followed by months of progression. If the record shows a finding the standard of care required to be worked up to completion, a workup that was never done or never tracked, and a cancer that timely diagnosis more likely than not would have caught at a curable stage, the breach, causation, and damages can all be built from the chart, the imaging reports, and the staging data.

General information for attorneys, not legal or medical advice. Standard-of-care, causation, and damages rules vary by jurisdiction — verify every standard, statute, and deadline against current authority in your venue, and rely on a qualified medical expert for the clinical analysis.

Questions? [email protected] · (856) 979-6525